NCT02217345View on ClinicalTrials.gov

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

August 10, 2021

Study Completion Date

September 13, 2021

Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
DRUG

Growth hormone

growth hormone, Genotropin (Pfizer)

DRUG

Placebo

placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02217345 - Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter